Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidaxomicin vs vancomycin for Clostridium difficile-associated diarrhoea
2006-004291-12Phase 3Completed
- Sponsor
- Optimer Pharmaceuticals, Inc.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fidaxomicin in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Optimer Pharmaceuticals, Inc. Primary endpoints: Primary cure rate in microbiologically evaluable population, Primary cure rate in Modified-Intent-to-Treat (mITT) population and 1 more. Started Jan 2007; status: completed.
02
Drugs
fidaxomicin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2006-004291-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004291-12.